New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 28, 2014
07:20 EDTCNATConatus Pharmaceuticals price target lowered to $14 from $16 at Stifel
Stifel cut its price target on Conatus as the firm thinks the extension of P2b ACLF data timelines due to slower than expected enrollment is negative. However, the firm keeps a Buy rating on the stock.
News For CNAT From The Last 14 Days
Check below for free stories on CNAT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 14, 2014
16:21 EDTCNATConatus files $150M mixed securities shelf
Subscribe for More Information
10:53 EDTCNATHigh option volume stocks
Subscribe for More Information
August 13, 2014
18:55 EDTCNATOn The Fly: After Hours Movers
UP AFTER EARNINGS: Aspen Technology (AZPN), up almost 3% after reporting better than expected Q4 results and giving Q1 and FY15 guidance on its earnings conference call. ALSO HIGHER: Kindred Healthcare (KND), up more than 1% after Point72 reported a 5.1% passive stake in the company. DOWN AFTER EARNINGS: Cisco Systems (CSCO), down 1.2% after reporting Q4 results, giving Q1 guidance, and announcing that it is cutting 8% of its workforce... Noodles & Company (NDLS), down 21.2% after reporting Q2 results and "tempering" its FY14 outlook... Conatus Pharmaceuticals (CNAT), down 13.6% after reporting Q2 results and announcing it is deferring the results of its NAFLD/NASH clinical trial to 1Q15. ALSO LOWER: Amgen (AMGN), down 2.15% after announcing the Phase 3 Kyprolis FOCUS clinical trial did not meet its primary endpoint.
16:57 EDTCNATConatus Phase 2 NAFLD/NASH clinical trial results announcement deferred to 1Q15
Subscribe for More Information
16:05 EDTCNATConatus reports Q2 EPS (34c), consensus (40c)
Subscribe for More Information
August 12, 2014
10:15 EDTCNATIntercept surges after reporting data for liver disease drug OCA
Subscribe for More Information
09:21 EDTCNATOn The Fly: Pre-market Movers
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use